Genetic modifiers of non-alcoholic fatty liver disease progression

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1812, Issue 11, 2011, Pages 1557-1566

  Anstee, Quentin M ^a   Daly, Ann K ^a   Day, Christopher P ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Gene; NAFLD; NASH; Polymorphism; Steatohepatitis

Indexed keywords

APOLIPOPROTEIN C3; APOLIPOPROTEIN E; CALCIUM BINDING PROTEIN; COLLAGEN TYPE 13; COLLAGEN TYPE XIII ALPHA 1; EF HAND CALCIUM BINDING DOMAIN 4B; ENDOTOXIN; FARNESYL DIPHOSPHATE FARNESYL TRANSFERASE 1; FATTY ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; KRUPPEL LIKE FACTOR; MANGANESE SUPEROXIDE DISMUTASE; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; MULTIDRUG RESISTANCE PROTEIN 2; NEUROCAN; PATATIN LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3; PHOSPHATIDYLETHANOLAMINE METHYLTRANSFERASE; PHOSPHOLIPASE; PREGNANCY ASSOCIATED ALPHA2 GLYCOPROTEIN; PREGNANE X RECEPTOR; PROTEIN FARNESYLTRANSFERASE; PROTIEN PHOSPHATASE 1 REGULATORY SUBUNIT 3B; REACTIVE OXYGEN METABOLITE; REGULATOR PROTEIN; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR 7 LIKE 2; TRANSFORMING GROWTH FACTOR BETA1; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

CARDIOVASCULAR RISK; CHROMOSOME 1; CHROMOSOME 11; CHROMOSOME 18; CHROMOSOME 4; CHROMOSOME 7; COMPUTER ASSISTED TOMOGRAPHY; CYTOKINE RELEASE; DISEASE COURSE; FATTY ACID BLOOD LEVEL; FIBROGENESIS; GENE LOCUS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOME ANALYSIS; GENOTYPE ENVIRONMENT INTERACTION; HISTOPATHOLOGY; HUMAN; INSULIN RESISTANCE; LIVER FIBROSIS; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; DISEASE PROGRESSION; FATTY LIVER; GENES; HUMANS; PHENOTYPE;

EID: 80053449479     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2011.07.017     Document Type: Review

References (121)

1. Ratziu V., Bellentani S., Cortez-Pinto H., Day C., Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J. Hepatol. 2010, 53:372-384.
2. Anstee Q.M., McPherson S., Day C.P. How Big A Problem is Non-Alcoholic Fatty Liver Disease?. BMJ 2011, 343:d3897. 10.1136/bmj.d3897.
3. Sanyal A.J., American Gastroenterological A. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002, 123:1705-1725.
4. Marchesini G., Brizi M., Morselli-Labate A.M., Bianchi G., Bugianesi E., McCullough A.J., Forlani G., Melchionda N. Association of nonalcoholic fatty liver disease with insulin resistance. Am. J. Med. 1999, 107:450-455.
5. Powell E.E., Cooksley W.G., Hanson R., Searle J., Halliday J.W., Powell L.W. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21years. Hepatology 1990, 11:74-80.
6. Argo C.K., Caldwell S.H. Epidemiology and natural history of non-alcoholic steatohepatitis. Clin. Liver. Dis. 2009, 13:511-531.
7. Anstee Q.M., Daly A.K., Day C.P. Genetics of alcoholic and nonalcoholic fatty liver disease. Semin. liver dis. 2011, 31:128-146.
8. Day C.P. Pathogenesis of steatohepatitis. Best Pract. Res. Clin. Gastroenterol. 2002, 16:663-678.
9. Anstee Q.M., Goldin R.D. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int. J. Exp. Pathol. 2006, 87:1-16.
10. Anstee Q.M. Animal models in nonalcoholic steatohepatitis research: utility and clinical translation. Liver int. 2011, 31:440-442.
11. Yamaguchi K., Yang L., McCall S., Huang J., Yu X.X., Pandey S.K., Bhanot S., Monia B.P., Li Y.X., Diehl A.M. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 2007, 45:1366-1374.
12. Malhi H., Gores G.J., Lemasters J.J. Apoptosis and necrosis in the liver: a tale of two deaths?. Hepatology 2006, 43:S31-S44.
13. Anstee Q.M., Concas D., Kudo H., Levene A., Pollard J., Charlton P., Thomas H.C., Thursz M.R., Goldin R.D. Impact of pan-caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis. J. Hepatol. 2010, 53:542-550.
14. Farrell G.C., Larter C.Z., Hou J.Y., Zhang R.H., Yeh M.M., Williams J. A. dela Pena, R. Francisco, S.R. Osvath, J. Brooling, N. Teoh, L.M. Sedger, Apoptosis in experimental NASH is associated with p53 activation and TRAIL receptor expression. J. Gastroenterol. Hepatol. 2009, 24:443-452.
15. Iredale J.P. Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J. Clin. Invest. 2007, 117:539-548.
16. A haplotype map of the human genome. Nature 2005, 437:1299-1320.
17. Frazer K.A., Ballinger D.G., Cox D.R., Hinds D.A., Stuve L.L., Gibbs R.A., Belmont J.W., Boudreau A., Hardenbol P., Leal S.M., Pasternak S., Wheeler D.A., Willis T.D., Yu F., Yang H., Zeng C., Gao Y., Hu H., Hu W., Li C., Lin W., Liu S., Pan H., Tang X., Wang J., Wang W., Yu J., Zhang B., Zhang Q., Zhao H., Zhou J., Gabriel S.B., Barry R., Blumenstiel B., Camargo A., Defelice M., Faggart M., Goyette M., Gupta S., Moore J., Nguyen H., Onofrio R.C., Parkin M., Roy J., Stahl E., Winchester E., Ziaugra L., Altshuler D., Shen Y., Yao Z., Huang W., Chu X., He Y., Jin L., Liu Y., Sun W., Wang H., Wang Y., Xiong X., Xu L., Waye M.M., Tsui S.K., Xue H., Wong J.T., Galver L.M., Fan J.B., Gunderson K., Murray S.S., Oliphant A.R., Chee M.S., Montpetit A., Chagnon F., Ferretti V., Leboeuf M., Olivier J.F., Phillips M.S., Roumy S., Sallee C., Verner A., Hudson T.J., Kwok P.Y., Cai D., Koboldt D.C., Miller R.D., Pawlikowska L., Taillon-Miller P., Xiao M., Tsui L.C., Mak W., Song Y.Q., Tam P.K., Nakamura Y., Kawaguchi T., Kitamoto T., Morizono T., Nagashima A., Ohnishi Y., Sekine A., Tanaka T., Tsunoda T., Deloukas P., Bird C.P., Delgado M., Dermitzakis E.T., Gwilliam R., Hunt S., Morrison J., Powell D., Stranger B.E., Whittaker P., Bentley D.R., Daly M.J., de Bakker P.I., Barrett J., Chretien Y.R., Maller J., McCarroll S., Patterson N., Pe'er I., Price A., Purcell S., Richter D.J., Sabeti P., Saxena R., Schaffner S.F., Sham P.C., Varilly P., Stein L.D., Krishnan L., Smith A.V., Tello-Ruiz M.K., Thorisson G.A., Chakravarti A., Chen P.E., Cutler D.J., Kashuk C.S., Lin S., Abecasis G.R., Guan W., Li Y., Munro H.M., Qin Z.S., Thomas D.J., McVean G., Auton A., Bottolo L., Cardin N., Eyheramendy S., Freeman C., Marchini J., Myers S., Spencer C., Stephens M., Donnelly P., Cardon L.R., Clarke G., Evans D.M., Morris A.P., Weir B.S., Mullikin J.C., Sherry S.T., Feolo M., Skol A., Zhang H., Matsuda I., Fukushima Y., Macer D.R., Suda E., Rotimi C.N., Adebamowo C.A., Ajayi I., Aniagwu T., Marshall P.A., Nkwodimmah C., Royal C.D., Leppert M.F., Dixon M., Peiffer A., Qiu R., Kent A., Kato K., Niikawa N., Adewole I.F., Knoppers B.M., Foster M.W., Clayton E.W., Watkin J., Muzny D., Nazareth L., Sodergren E., Weinstock G.M., Yakub I., Birren B.W., Wilson R.K., Fulton L.L., Rogers J., Burton J., Carter N.P., Clee C.M., Griffiths M., Jones M.C., McLay K., Plumb R.W., Ross M.T., Sims S.K., Willey D.L., Chen Z., Han H., Kang L., Godbout M., Wallenburg J.C., L'Archeveque P., Bellemare G., Saeki K., An D., Fu H., Li Q., Wang Z., Wang R., Holden A.L., Brooks L.D., McEwen J.E., Guyer M.S., Wang V.O., Peterson J.L., Shi M., Spiegel J., Sung L.M., Zacharia L.F., Collins F.S., Kennedy K., Jamieson R., Stewart J. A second generation human haplotype map of over 3.1 million SNPs. Nature 2007, 449:851-861.
18. Sachidanandam R., Weissman D., Schmidt S.C., Kakol J.M., Stein L.D., Marth G., Sherry S., Mullikin J.C., Mortimore B.J., Willey D.L., Hunt S.E., Cole C.G., Coggill P.C., Rice C.M., Ning Z., Rogers J., Bentley D.R., Kwok P.Y., Mardis E.R., Yeh R.T., Schultz B., Cook L., Davenport R., Dante M., Fulton L., Hillier L., Waterston R.H., McPherson J.D., Gilman B., Schaffner S., Van Etten W.J., Reich D., Higgins J., Daly M.J., Blumenstiel B., Baldwin J., Stange-Thomann N., Zody M.C., Linton L., Lander E.S., Altshuler D. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 2001, 409:928-933.
19. Manolio T.A., Brooks L.D., Collins F.S. A HapMap harvest of insights into the genetics of common disease. J. Clin. Invest. 2008, 118:1590-1605.
20. Hardy J., Singleton A. Genomewide association studies and human disease. N. Engl. J. Med. 2009, 360:1759-1768.
21. Cirulli E.T., Goldstein D.B. Uncovering the roles of rare variants in common disease through whole-genome sequencing. Nat. Rev. Genet. 2010, 11:415-425.
22. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007, 447:661-678.
23. Yuan X., Waterworth D., Perry J.R., Lim N., Song K., Chambers J.C., Zhang W., Vollenweider P., Stirnadel H., Johnson T., Bergmann S., Beckmann N.D., Li Y., Ferrucci L., Melzer D., Hernandez D., Singleton A., Scott J., Elliott P., Waeber G., Cardon L., Frayling T.M., Kooner J.S., Mooser V. Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes. Am. J. Hum. Genet. 2008, 83:520-528.
24. Daly A.K., Donaldson P.T., Bhatnagar P., Shen Y. I. Pe'er, A. Floratos, M.J. Daly, D.B. Goldstein, S. John, M.R. Nelson, J. Graham, B.K. Park, J.F. Dillon, W. Bernal, H.J. Cordell, M. Pirmohamed, G.P. Aithal, C.P. Day, D. Study, S.A.E.C. International, HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat. Genet. 2009, 41:816-819.
25. Lucena M.I., Molokhia M., Shen Y., Urban T.J., Aithal G.P., Andrade R.J., Day C.P., Ruiz-Cabello F., Donaldson P.T., Stephens C., Pirmohamed M., Romero-Gomez M., Navarro J.M., Fontana R.J., Miller M., Groome M., Bondon-Guitton E., Conforti A., Stricker B.H., Carvajal A., Ibanez L., Yue Q.Y., Eichelbaum M., Floratos A., Pe'er I., Daly M.J., Goldstein D.B., Dillon J.F., Nelson M.R., Watkins P.B., Daly A.K. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology 2011, 141:338-347.
26. Buch S., Schafmayer C., Volzke H., Becker C., Franke A., von Eller-Eberstein H., Kluck C., Bassmann I., Brosch M., Lammert F., Miquel J.F., Nervi F., Wittig M., Rosskopf D., Timm B., Holl C., Seeger M., ElSharawy A., Lu T., Egberts J., Fandrich F., Folsch U.R., Krawczak M., Schreiber S., Nurnberg P., Tepel J., Hampe J. A genome-wide association scan identifies the hepatic cholesterol transporter ABCG8 as a susceptibility factor for human gallstone disease. Nat. Genet. 2007, 39:995-999.
27. Hirschfield G.M., Liu X., Xu C., Lu Y., Xie G., Gu X., Walker E.J., Jing K., Juran B.D., Mason A.L., Myers R.P., Peltekian K.M., Ghent C.N., Coltescu C., Atkinson E.J., Heathcote E.J., Lazaridis K.N., Amos C.I., Siminovitch K.A. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N. Engl. J. Med. 2009, 360:2544-2555.
28. Liu X., Invernizzi P., Lu Y., Kosoy R., Bianchi I., Podda M., Xu C., Xie G., Macciardi F., Selmi C., Lupoli S., Shigeta R., Ransom M., Lleo A., Lee A.T., Mason A.L., Myers R.P., Peltekian K.M., Ghent C.N., Bernuzzi F., Zuin M., Rosina F., Borghesio E., Floreani A., Lazzari R., Niro G., Andriulli A., Muratori L., Muratori P., Almasio P.L., Andreone P., Margotti M., Brunetto M., Coco B., Alvaro D., Bragazzi M.C., Marra F., Pisano A., Rigamonti C., Colombo M., Marzioni M., Benedetti A., Fabris L., Strazzabosco M., Portincasa P., Palmieri V.O., Tiribelli C., Croce L., Bruno S., Rossi S., Vinci M., Prisco C., Mattalia A., Toniutto P., Picciotto A., Galli A., Ferrari C., Colombo S., Casella G., Morini L., Caporaso N., Colli A., Spinzi G., Montanari R., Gregersen P.K., Heathcote E.J., Hirschfield G.M., Siminovitch K.A., Amos C.I., Gershwin M.E., Seldin M.F. Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat. Genet. 2010, 42:658-660.
29. Mells G.F., Floyd J.A., Morley K.I., Cordell H.J., Franklin C.S., Shin S.Y., Heneghan M.A., Neuberger J.M., Donaldson P.T., Day D.B., Ducker S.J., Muriithi A.W., Wheater E.F., Hammond C.J., Dawwas M.F., Jones D.E., Peltonen L., Alexander G.J., Sandford R.N., Anderson C.A. Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis. Nat. Genet. 2011, 43:329-332.
30. Romeo S., Kozlitina J., Xing C., Pertsemlidis A., Cox D., Pennacchio L.A., Boerwinkle E., Cohen J.C., Hobbs H.H. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 2008, 40:1461-1465.
31. Chalasani N., Guo X., Loomba R., Goodarzi M.O., Haritunians T., Kwon S., Cui J., Taylor K.D., Wilson L., Cummings O.W., Chen Y.D., Rotter J.I. Genome-wide association study identifies variants associated with histologic features of nonalcoholic fatty liver disease. Gastroenterology 2010, 139:1567-1576.
32. Speliotes E.K., Yerges-Armstrong L.M., Wu J., Hernaez R., Kim L.J., Palmer C.D., Gudnason V., Eiriksdottir G., Garcia M.E., Launer L.J., Nalls M.A., Clark J.M., Mitchell B.D., Shuldiner A.R., Butler J.L., Tomas M., Hoffmann U., Hwang S.-J., Massaro J.M., O'Donnell C.J., Sahani D.V., Salomaa V., Schadt E.E., Schwartz S.M., Siscovick D.S., Voight B.F., Carr J.J., Feitosa M.F., Harris T.B., Fox C.S., Smith A.V., Kao W.H.L., Hirschhorn J.N., Borecki I.B., Nash C.R.N., Consortium G., Investigators M., Consortium G. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet. 2011, 7:e1001324.
33. Kamatani Y., Wattanapokayakit S., Ochi H., Kawaguchi T., Takahashi A., Hosono N., Kubo M., Tsunoda T., Kamatani N., Kumada H., Puseenam A., Sura T., Daigo Y., Chayama K., Chantratita W., Nakamura Y., Matsuda K. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat. Genet. 2009, 41:591-595.
34. Ge D., Fellay J., Thompson A.J., Simon J.S., Shianna K.V., Urban T.J., Heinzen E.L., Qiu P., Bertelsen A.H., Muir A.J., Sulkowski M., McHutchison J.G., Goldstein D.B. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
35. Suppiah V., Moldovan M., Ahlenstiel G., Berg T., Weltman M., Abate M.L., Bassendine M., Spengler U., Dore G.J., Powell E., Riordan S., Sheridan D., Smedile A., Fragomeli V., Muller T., Bahlo M., Stewart G.J., Booth D.R., George J. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat. Genet. 2009, 41:1100-1104.
36. Miele L., Beale G., Patman G., Nobili V., Leathart J., Grieco A., Abate M., Friedman S.L., Narla G., Bugianesi E., Day C.P., Reeves H.L. The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease. Gastroenterology 2008, 135:282-291. e281.
37. Wright M., Goldin R., Hellier S., Knapp S., Frodsham A., Hennig B., Hill A., Apple R., Cheng S., Thomas H., Thursz M. Factor V Leiden polymorphism and the rate of fibrosis development in chronic hepatitis C virus infection. Gut 2003, 52:1206-1210.
38. Victor R.G., Haley R.W., Willett D.L., Peshock R.M., Vaeth P.C., Leonard D., Basit M., Cooper R.S., Iannacchione V.G., Visscher W.A., Staab J.M., Hobbs H.H. The Dallas Heart Study: a population-based probability sample for the multidisciplinary study of ethnic differences in cardiovascular health. Am. J. Cardiol. 2004, 93:1473-1480.
39. Cobbold J.F., Anstee Q.M., Goldin R.D., Williams H.R., Matthews H.C., North B.V., Absalom N., Thomas H.C., Thursz M.R., Cox R.D., Taylor-Robinson S.D., Cox I.J. Phenotyping murine models of non-alcoholic fatty liver disease through metabolic profiling of intact liver tissue. Clin. Sci. (Lond) 2009, 116:403-413.
40. Siegelman E.S., Rosen M.A. Imaging of hepatic steatosis. Semin. Liver Dis. 2001, 21:71-80.
41. Romeo S., Huang-Doran I., Baroni M.G., Kotronen A. Unravelling the pathogenesis of fatty liver disease: patatin-like phospholipase domain-containing 3 protein. Curr. Opin. Lipidol. 2010, 21:247-252.
42. Ballestri S., Day C.P., Daly A.K. Polymorphism in the farnesyl diphosphate farnesyl transferase 1 gene and nonalcoholic fatty liver disease severity. Gastroenterology 2011, 140:1694-1695.
43. Fawcett K.A., Barroso I. The genetics of obesity: FTO leads the way. Trends Genet. 2010, 26:266-274.
44. Ingalls A.M., Dickie M.M., Snell G.D. Obese, a new mutation in the house mouse. J. Hered. 1950, 41:317-318.
45. Hummel K.P., Dickie M.M., Coleman D.L. Diabetes, a new mutation in the mouse. Science 1966, 153:1127-1128.
46. Chalasani N., Crabb D.W., Cummings O.W., Kwo P.Y., Asghar A., Pandya P.K., Considine R.V. Does leptin play a role in the pathogenesis of human nonalcoholic steatohepatitis?. Am. J. Gastroenterol. 2003, 98:2771-2776.
47. Frayling T.M., Timpson N.J., Weedon M.N., Zeggini E., Freathy R.M., Lindgren C.M., Perry J.R., Elliott K.S., Lango H., Rayner N.W., Shields B., Harries L.W., Barrett J.C., Ellard S., Groves C.J., Knight B., Patch A.M., Ness A.R., Ebrahim S., Lawlor D.A., Ring S.M., Ben-Shlomo Y., Jarvelin M.R., Sovio U., Bennett A.J., Melzer D., Ferrucci L., Loos R.J., Barroso I., Wareham N.J., Karpe F., Owen K.R., Cardon L.R., Walker M., Hitman G.A., Palmer C.N., Doney A.S., Morris A.D., Smith G.D., Hattersley A.T., McCarthy M.I. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 2007, 316:889-894.
48. Church C., Lee S., Bagg E.A., McTaggart J.S., Deacon R., Gerken T., Lee A., Moir L., Mecinovic J., Quwailid M.M., Schofield C.J., Ashcroft F.M., Cox R.D. A mouse model for the metabolic effects of the human fat mass and obesity associated FTO gene. PLoS Genet. 2009, 5:e1000599.
49. Fischer J., Koch L., Emmerling C., Vierkotten J., Peters T., Bruning J.C., Ruther U. Inactivation of the Fto gene protects from obesity. Nature 2009, 458:894-898.
50. Kelly M.L., Moir L., Jones L., Whitehill E., Anstee Q.M., Goldin R.D., Hough A., Cheeseman M., Jansson J.O., Peters J., Cox R.D. A missense mutation in the non-neural G-protein alpha-subunit isoforms modulates susceptibility to obesity. Int. J. Obes. (Lond) 2009, 33:507-518.
51. McCarthy M.I., Zeggini E. Genome-wide association studies in type 2 diabetes. Curr. Diab. Rep. 2009, 9:164-171.
52. Dongiovanni P., Valenti L., Rametta R., Daly A.K., Nobili V., Mozzi E., Leathart J.B., Pietrobattista A., Burt A.D., Maggioni M., Fracanzani A.L., Lattuada E., Zappa M.A., Roviaro G., Marchesini G., Day C.P., Fargion S. Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease. Gut 2010, 59:267-273.
53. Carulli L., Canedi I., Rondinella S., Lombardini S., Ganazzi D., Fargion S., De Palma M., Lonardo A., Ricchi M., Bertolotti M., Carulli N., Loria P. Genetic polymorphisms in non-alcoholic fatty liver disease: interleukin-6-174G/C polymorphism is associated with non-alcoholic steatohepatitis. Dig. Liver Dis. 2009, 41:823-828.
54. Musso G., Gambino R., De Michieli F., Durazzo M., Pagano G., Cassader M. Adiponectin gene polymorphisms modulate acute adiponectin response to dietary fat: possible pathogenetic role in NASH. Hepatology 2008, 47:1167-1177.
55. Kotronen A., Yki-Jarvinen H., Aminoff A., Bergholm R., Pietilainen K.H., Westerbacka J., Talmud P.J., Humphries S.E., Hamsten A., Isomaa B., Groop L., Orho-Melander M., Ehrenborg E., Fisher R.M. Genetic variation in the ADIPOR2 gene is associated with liver fat content and its surrogate markers in three independent cohorts. Eur. J. Endocrinol. 2009, 160:593-602.
56. Hui Y., Yu-Yuan L., Yu-Qiang N., Wei-Hong S., Yan-Lei D., Xiao-Bo L., Yong-Jian Z. Effect of peroxisome proliferator-activated receptors-gamma and co-activator-1alpha genetic polymorphisms on plasma adiponectin levels and susceptibility of non-alcoholic fatty liver disease in Chinese people. Liver int. 2008, 28:385-392.
57. Bradbury M.W., Berk P.D. Lipid metabolism in hepatic steatosis. Clin. Liver Dis. 2004, 8:639-671. xi.
58. Koteish A., Diehl A.M. Animal models of steatosis. Semin. Liver Dis. 2001, 21:89-104.
59. Kotronen A., Johansson L.E., Johansson L.M., Roos C., Westerbacka J., Hamsten A., Bergholm R., Arkkila P., Arola J., Kiviluoto T., Fisher R.M., Ehrenborg E., Orho-Melander M., Ridderstrale M., Groop L., Yki-Jarvinen H. A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans. Diabetologia 2009, 52:1056-1060.
60. Sookoian S., Castano G.O., Burgueno A.L., Gianotti T.F., Rosselli M.S., Pirola C.J. A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity. J. Lipid Res. 2009, 50:2111-2116.
61. Kantartzis K., Peter A., Machicao F., Machann J., Wagner S., Konigsrainer I., Konigsrainer A., Schick F., Fritsche A., Haring H.U., Stefan N. Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. Diabetes 2009, 58:2616-2623.
62. Rotman Y., Koh C., Zmuda J.M., Kleiner D.E., Liang T.J. The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology 2010, 52:894-903.
63. Romeo S., Sentinelli F., Cambuli V.M., Incani M., Congiu T., Matta V., Pilia S., Huang-Doran I., Cossu E., Loche S., Baroni M.G. The 148M allele of the PNPLA3 gene is associated with indices of liver damage early in life. J. Hepatol. 2010, 53:335-338.
64. Valenti L., Alisi A., Galmozzi E., Bartuli A., Del Menico B., Alterio A., Dongiovanni P., Fargion S., Nobili V. I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease. Hepatology 2010, 52:1274-1280.
65. Santoro N., Kursawe R., D'Adamo E., Dykas D.J., Zhang C.K., Bale A.E., Cali A.M., Narayan D., Shaw M.M., Pierpont B., Savoye M., Lartaud D., Eldrich S., Cushman S.W., Zhao H., Shulman G.I., Caprio S. A common variant in the patatin-like phospholipase 3 gene (PNPLA3) is associated with fatty liver disease in obese children and adolescents. Hepatology 2010, 52:1281-1290.
66. Kollerits B., Coassin S., Kiechl S., Hunt S.C., Paulweber B., Willeit J., Brandstatter A., Lamina C., Adams T.D., Kronenberg F. A common variant in the adiponutrin gene influences liver enzyme values. J. Med. Genet. 2010, 47:116-119.
67. Tian C., Stokowski R.P., Kershenobich D., Ballinger D.G., Hinds D.A. Variant in PNPLA3 is associated with alcoholic liver disease. Nat. Genet. 2010, 42:21-23.
68. Seth D., Daly A.K., Haber P.S., Day C.P. Patatin-like phospholipase domain containing 3: a case in point linking genetic susceptibility for alcoholic and nonalcoholic liver disease. Hepatology 2010, 51:1463-1465.
69. Stickel F., Buch S., Lau K., Zu Schwabedissen H.M., Berg T., Ridinger M., Rietschel M., Schafmayer C., Braun F., Hinrichsen H., Gunther R., Arlt A., Seeger M., Muller S., Seitz H.K., Soyka M., Lerch M., Lammert F., Sarrazin C., Kubitz R., Haussinger D., Hellerbrand C., Broring D., Schreiber S., Kiefer F., Spanagel R., Mann K., Datz C., Krawczak M., Wodarz N., Volzke H., Hampe J. Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in Caucasians. Hepatology 2010.
70. Valenti L., Rumi M., Galmozzi E., Aghemo A., Del Menico B., De Nicola S., Dongiovanni P., Maggioni M., Fracanzani A.L., Rametta R., Colombo M., Fargion S. Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology 2011, 53:791-799.
71. Zimmermann R., Strauss J.G., Haemmerle G., Schoiswohl G., Birner-Gruenberger R., Riederer M., Lass A., Neuberger G., Eisenhaber F., Hermetter A., Zechner R. Fat mobilization in adipose tissue is promoted by adipose triglyceride lipase. Science 2004, 306:1383-1386.
72. Romeo S., Sentinelli F., Dash S., Yeo G.S., Savage D.B., Leonetti F., Capoccia D., Incani M., Maglio C., Iacovino M., O'Rahilly S., Baroni M.G. Morbid obesity exposes the association between PNPLA3 I148M (rs738409) and indices of hepatic injury in individuals of European descent. Int. J. Obes. (Lond) 2010, 34:190-194.
73. Speliotes E.K., Butler J.L., Palmer C.D., Voight B.F., Hirschhorn J.N. PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease. Hepatology 2010, 52:904-912.
74. Huang Y., He S., Li J.Z., Seo Y.K., Osborne T.F., Cohen J.C., Hobbs H.H. A feed-forward loop amplifies nutritional regulation of PNPLA3. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:7892-7897.
75. Wilson P.A., Gardner S.D., Lambie N.M., Commans S.A., Crowther D.J. Characterization of the human patatin-like phospholipase family. J. Lipid. Res. 2006, 47:1940-1949.
76. Hoekstra M., Li Z., Kruijt J.K., Van Eck M., Van Berkel T.J., Kuiper J. The expression level of non-alcoholic fatty liver disease-related gene PNPLA3 in hepatocytes is highly influenced by hepatic lipid status. J. Hepatol. 2010, 52:244-251.
77. Lake A.C., Sun Y., Li J.L., Kim J.E., Johnson J.W., Li D., Revett T., Shih H.H., Liu W., Paulsen J.E., Gimeno R.E. Expression, regulation, and triglyceride hydrolase activity of Adiponutrin family members. J. Lipid. Res. 2005, 46:2477-2487.
78. He S., McPhaul C., Li J.Z., Garuti R., Kinch L., Grishin N.V., Cohen J.C., Hobbs H.H. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J. Biol. Chem. 2010, 285:6706-6715.
79. Jenkins C.M., Mancuso D.J., Yan W., Sims H.F., Gibson B., Gross R.W. Identification, cloning, expression, and purification of three novel human calcium-independent phospholipase A2 family members possessing triacylglycerol lipase and acylglycerol transacylase activities. J. Biol. Chem. 2004, 279:48968-48975.
80. Lonardo A., Lombardini S., Scaglioni F., Carulli L., Ricchi M., Ganazzi D., Adinolfi L.E., Ruggiero G., Carulli N., Loria P. Hepatic steatosis and insulin resistance: does etiology make a difference?. J. Hepatol. 2006, 44:190-196.
81. Namikawa C., Shu-Ping Z., Vyselaar J.R., Nozaki Y., Nemoto Y., Ono M., Akisawa N., Saibara T., Hiroi M., Enzan H., Onishi S. Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis. J. Hepatol. 2004, 40:781-786.
82. Bernard S., Touzet S., Personne I., Lapras V., Bondon P.J., Berthezene F., Moulin P. Association between microsomal triglyceride transfer protein gene polymorphism and the biological features of liver steatosis in patients with type II diabetes. Diabetologia 2000, 43:995-999.
83. Oliveira C.P., Stefano J.T., Cavaleiro A.M., Zanella Fortes M.A., Vieira S.M., Rodrigues Lima V.M., Santos T.E., Santos V.N., de Azevedo Salgado A.L., Parise E.R., Ferreira Alves V.A., Carrilho F.J., Correa-Giannella M.L. Association of polymorphisms of glutamate-cystein ligase and microsomal triglyceride transfer protein genes in non-alcoholic fatty liver disease. J. Gastroenterol. Hepatol. 2010, 25:357-361.
84. Dong H., Wang J., Li C., Hirose A., Nozaki Y., Takahashi M., Ono M., Akisawa N., Iwasaki S., Saibara T., Onishi S. The phosphatidylethanolamine N-methyltransferase gene V175M single nucleotide polymorphism confers the susceptibility to NASH in Japanese population. J. Hepatol. 2007, 46:915-920.
85. Song J., da Costa K.A., Fischer L.M., Kohlmeier M., Kwock L., Wang S., Zeisel S.H. Polymorphism of the PEMT gene and susceptibility to nonalcoholic fatty liver disease (NAFLD). FASEB J. 2005, 19:1266-1271.
86. Petersen K.F., Dufour S., Hariri A., Nelson-Williams C., Foo J.N., Zhang X.M., Dziura J., Lifton R.P., Shulman G.I. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N. Engl. J. Med. 2010, 362:1082-1089.
87. Kozlitina J., Boerwinkle E., Cohen J.C., Hobbs H.H. Dissociation between APOC3 variants, hepatic triglyceride content and insulin resistance. Hepatology 2011, 53:467-474.
88. L. Valenti, V. Nobili, A. Al-Serri, R. Rametta, J.B.S. Leathart, M.A. Zappa, P. Dongiovanni, A.L. Fracanzani, A. Alterio, G. Roviaro, A.K. Daly, S. Fargion, C.P. Day, The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage in patients with nonalcoholic fatty liver, Journal of Hepatology, in press (2011).
89. Zhou J., Zhai Y., Mu Y., Gong H., Uppal H., Toma D., Ren S., Evans R.M., Xie W. A novel pregnane X receptor-mediated and sterol regulatory element-binding protein-independent lipogenic pathway. J. Biol. Chem. 2006, 281:15013-15020.
90. Zhang B., Xie W., Krasowski M.D. PXR: a xenobiotic receptor of diverse function implicated in pharmacogenetics. Pharmacogenomics 2008, 9:1695-1709.
91. Sookoian S., Castano G.O., Burgueno A.L., Gianotti T.F., Rosselli M.S., Pirola C.J. The nuclear receptor PXR gene variants are associated with liver injury in nonalcoholic fatty liver disease. Pharmacogenet. Genomics 2010, 20:1-8.
92. Musso G., Gambino R., Pacini G., Pagano G., Durazzo M., Cassader M. Transcription factor 7-like 2 polymorphism modulates glucose and lipid homeostasis, adipokine profile, and hepatocyte apoptosis in NASH. Hepatology 2009, 49:426-435.
93. Sazci A., Akpinar G., Aygun C., Ergul E., Senturk O., Hulagu S. Association of apolipoprotein E polymorphisms in patients with non-alcoholic steatohepatitis. Dig. Dis. Sci. 2008, 53:3218-3224.
94. Demirag M.D., Onen H.I., Karaoguz M.Y., Dogan I., Karakan T., Ekmekci A., Guz G. Apolipoprotein E gene polymorphism in nonalcoholic fatty liver disease. Dig. Dis. Sci. 2007, 52:3399-3403.
95. Sookoian S., Castano G., Gianotti T.F., Gemma C., Pirola C.J. Polymorphisms of MRP2 (ABCC2) are associated with susceptibility to nonalcoholic fatty liver disease. J. Nutr. Biochem. 2009, 20:765-770.
96. George D.K., Goldwurm S., MacDonald G.A., Cowley L.L., Walker N.I., Ward P.J., Jazwinska E.C., Powell L.W. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998, 114:311-318.
97. Nelson J.E., Bhattacharya R., Lindor K.D., Chalasani N., Raaka S., Heathcote E.J., Miskovsky E., Shaffer E., Rulyak S.J., Kowdley K.V. HFE C282Y mutations are associated with advanced hepatic fibrosis in Caucasians with nonalcoholic steatohepatitis. Hepatology 2007, 46:723-729.
98. Bugianesi E., Manzini P., D'Antico S., Vanni E., Longo F., Leone N., Massarenti P., Piga A., Marchesini G., Rizzetto M. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 2004, 39:179-187.
99. Valenti L., Fracanzani A.L., Bugianesi E., Dongiovanni P., Galmozzi E., Vanni E., Canavesi E., Lattuada E., Roviaro G., Marchesini G., Fargion S. HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 2010, 138:905-912.
100. Raszeja-Wyszomirska J., Kurzawski G., Lawniczak M., Miezynska-Kurtycz J., Lubinski J. Nonalcoholic fatty liver disease and HFE gene mutations: a Polish study. World J. Gastroenterol. 2010, 16:2531-2536.
101. A. Al-Serri, Q.M. Anstee, L. Valenti, V. Nobili, J.B.S. Leathart, P. Dongiovanni, J. Patch, A. Fracanzani, S. Fargion, C.P. Day, A.K. Daly, The SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies, Journal of Hepatology, in press (2011), doi:. doi:10.1016/j.jhep.2011.05.029.
102. Guo J., Loke J., Zheng F., Hong F., Yea S., Fukata M., Tarocchi M., Abar O.T., Huang H., Sninsky J.J., Friedman S.L. Functional linkage of cirrhosis-predictive single nucleotide polymorphisms of Toll-like receptor 4 to hepatic stellate cell responses. Hepatology 2009, 49:960-968.
103. Huang H., Shiffman M.L., Friedman S., Venkatesh R., Bzowej N., Abar O.T., Rowland C.M., Catanese J.J., Leong D.U., Sninsky J.J., Layden T.J., Wright T.L., White T., Cheung R.C. A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology 2007, 46:297-306.
104. Spruss A., Kanuri G., Wagnerberger S., Haub S., Bischoff S.C., Bergheim I. Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. Hepatology 2009, 50:1094-1104.
105. Day C.P., Leathart J., McTernan P., Mathew C., Daly A. Genetic evidence for a role of gut flora in the pathogenesis of NASH in humans. Hepatology 2006, 44(Suppl. 1):261A.
106. Baldini M., Lohman I.C., Halonen M., Erickson R.P., Holt P.G., Martinez F.D. A Polymorphism in the 5' flanking region of the CD14 gene is associated with circulating soluble CD14 levels and with total serum immunoglobulin E. Am. J. Respir. Cell. Mol. Biol. 1999, 20:976-983.
107. McClain C., Hill D., Schmidt J., Diehl A.M. Cytokines and alcoholic liver disease. Semin. Liver Dis. 1993, 13:170-182.
108. Valenti L., Fracanzani A.L., Dongiovanni P., Santorelli G., Branchi A., Taioli E., Fiorelli G., Fargion S. Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 2002, 122:274-280.
109. Tokushige K., Takakura M., Tsuchiya-Matsushita N., Taniai M., Hashimoto E., Shiratori K. Influence of TNF gene polymorphisms in Japanese patients with NASH and simple steatosis. J. Hepatol. 2007, 46:1104-1110.
110. Bataller R., North K.E., Brenner D.A. Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal. Hepatology 2003, 37:493-503.
111. Anstee Q.M., Goldin R.D., Wright M., Martinelli A., Cox R., Thursz M.R. Coagulation status modulates murine hepatic fibrogenesis: implications for the development of novel therapies. J. Thromb. Haemost. 2008, 6:1336-1343.
112. Papatheodoridis G.V., Papakonstantinou E., Andrioti E., Cholongitas E., Petraki K., Kontopoulou I., Hadziyannis S.J. Thrombotic risk factors and extent of liver fibrosis in chronic viral hepatitis. Gut 2003, 52:404-409.
113. Papatheodoridis G.V., Chrysanthos N., Cholongitas E., Pavlou E., Apergis G., Tiniakos D.G., Andrioti E., Theodossiades G., Archimandritis A.J. Thrombotic risk factors and liver histologic lesions in non-alcoholic fatty liver disease. J. Hepatol. 2009, 51:931-938.
114. Anstee Q.M., Wright M., Goldin R., Thursz M.R. Parenchymal extinction: coagulation and hepatic fibrogenesis. Clin. Liver Dis. 2009, 13:117-126.
115. Oakley F., Teoh V., Ching A.S.G., Bataller R., Colmenero J., Jonsson J.R., Eliopoulos A.G., Watson M.R., Manas D., Mann D.A. Angiotensin II activates I kappaB kinase phosphorylation of RelA at Ser 536 to promote myofibroblast survival and liver fibrosis. Gastroenterology 2009, 136:2334-2344. e2331.
116. Yoneda M., Hotta K., Nozaki Y., Endo H., Uchiyama T., Mawatari H., Iida H., Kato S., Fujita K., Takahashi H., Kirikoshi H., Kobayashi N., Inamori M., Abe Y., Kubota K., Saito S., Maeyama S., Wada K., Nakajima A. Association between angiotensin II type 1 receptor polymorphisms and the occurrence of nonalcoholic fatty liver disease. Liver Int. 2009, 29:1078-1085.
117. Dixon J.B., Bhathal P.S., Jonsson J.R., Dixon A.F., Powell E.E., O'Brien P.E. Pro-fibrotic polymorphisms predictive of advanced liver fibrosis in the severely obese. J. Hepatol. 2003, 39:967-971.
118. Yokohama S., Yoneda M., Haneda M., Okamoto S., Okada M., Aso K., Hasegawa T., Tokusashi Y., Miyokawa N., Nakamura K. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004, 40:1222-1225.
119. Ratziu V., Lalazar A., Wong L., Dang Q., Collins C., Shaulian E., Jensen S., Friedman S.L. Zf9, a Kruppel-like transcription factor up-regulated in vivo during early hepatic fibrosis. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:9500-9505.
120. Starkel P., Sempoux C., Leclercq I., Herin M., Deby C., Desager J.P., Horsmans Y. Oxidative stress, KLF6 and transforming growth factor-beta up-regulation differentiate non-alcoholic steatohepatitis progressing to fibrosis from uncomplicated steatosis in rats. J. Hepatol. 2003, 39:538-546.
121. Narla G., Difeo A., Reeves H.L., Schaid D.J., Hirshfeld J., Hod E., Katz A., Isaacs W.B., Hebbring S., Komiya A., McDonnell S.K., Wiley K.E., Jacobsen S.J., Isaacs S.D., Walsh P.C., Zheng S.L., Chang B.L., Friedrichsen D.M., Stanford J.L., Ostrander E.A., Chinnaiyan A.M., Rubin M.A., Xu J., Thibodeau S.N., Friedman S.L., Martignetti J.A. A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. Cancer Res. 2005, 65:1213-1222.